Welcome to the e-CCO Library!

DOP86: Mirikizumab-induced upregulation of colonic transcripts correlates with improvements in stool frequency in a phase 2 study of patients with moderately to severely active Ulcerative Colitis
Year: 2022
Source: ECCO'22
Authors: Steere, B.(1);Powell, N.(2);Higgs, R.(1);Wang, Y.C.(1);Milch, C.(1);Sandborn, W.J.(3);Sands, B.E.(4);Reinisch, W.(5);D'Haens, G.(6);Krishnan, G.(1);
Created: Friday, 11 February 2022, 3:52 PM
DOP86: Risk for development of inflammatory bowel disease under inhibition of interleukin 17 in psoriasis, psoriatic arthritis, ankylosing spondylitis and rheumatoid arthritis: a review and meta-analysis
Year: 2019
Source: ECCO'19 Copenhagen
Authors: Wolfgang Eigner
Created: Tuesday, 28 May 2019, 3:32 PM
Epidemiology, Crohn’s disease, Ulcerative colitis, Immunology
Files: 1
DOP86: Subcutaneous infliximab (CT-P13 SC) as maintenance therapy for Crohn's disease: A phase 3, randomised, placebo-controlled study (LIBERTY-CD).
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Colombel, J.F.(1)*;Hanauer, S.B.(2);Sandborn, W.(3);Sands, B.E.(4);Schreiber, S.(5);Danese, S.(6);Kierkus, J.(7);Kulynych, R.(8);Klopocka, M.(9);Lahat, A.(10);Gonciarz, M.(11);Osipenko, M.(12);Borzan, V.(13);Kowalski, M.(14);Saenko, D.(15);Sardinov, R.(16);Kim, S.(17);Bae, Y.(17);Lee, S.(17);Yang, S.(17);Lee, J.(17);Lee, S.J.(18);Lee, S.G.(18);Park, G.(18);
Created: Friday, 14 July 2023, 10:43 AM
DOP86: Subcutaneous infliximab (CT-P13 SC) as maintenance therapy for Crohn’s disease: A phase 3, randomised, placebo-controlled study (LIBERTY-CD).
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Jean-Frédéric Colombel
Created: Friday, 14 July 2023, 2:22 PM
DOP87 SUCNR1 a novel key protagonist in fistula development
Year: 2020
Source:

ECCO'20 Vienna

Authors:

C. Bauset1, L. Gisbert-Ferrandiz1, D. Ortiz-Masia2, S. Coll1, C. Mamie3, M. Scharl3, S. Calatayud1, M.D. Barrachina1, J. Cosín-Roger4

Created: Thursday, 30 January 2020, 10:12 AM
DOP87: Association of histologic measurement with endoscopic outcomes after one year of treatment with mirikizumab in patients with moderate to severe Crohn’s Disease
Year: 2022
Source: ECCO'22
Authors: Magro, F.(1);De Hertogh, G.(2);Protic, M.(3);Chan, L.S.(3);Pollack, P.(3);Feagan, B.G.(4);Harpaz, N.(5);Pai, R.(6);Reinisch, W.(7);
Created: Friday, 11 February 2022, 3:52 PM
DOP87: Characterization of pathologic fibroblast and macrophage cell populations in colonic Crohn’s Disease with spatial transcriptomics.
Year: 2024
Source: ECCO'24 Stockholm
Authors: Gudiño, Victoria
Created: Tuesday, 30 April 2024, 5:03 PM
DOP87: Disease clearance as a new therapeutic target in patients with Ulcerative Colitis: A multicenter retrospective cohort study
Year: 2021
Source: ECCO'21 Virtual
Authors: D'Amico, F.(1);Fiorino, G.(1);Massarini, E.(1);Solitano, V.(1);Guillo, L.(2);Allocca, M.(1);Furfaro, F.(3);Zilli, A.(3);Bonovas, S.(1);Peyrin-Biroulet, L.(4);Danese, S.(5)
Created: Wednesday, 2 June 2021, 4:12 PM
DOP87: Multi-parameter data-sets are required to identify the true prevalence of IBD: The Lothian IBD Registry (LIBDR)
Year: 2019
Source: ECCO'19 Copenhagen
Authors: Gareth-Rhys Jones
Created: Tuesday, 28 May 2019, 3:32 PM
Epidemiology, Crohn’s disease, Ulcerative colitis, IBDU
Files: 1
DOP87: Multi-parameter datasets are required to identify the true prevalence of IBD: The Lothian IBD Registry (LIBDR)
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

G-R. Jones*1,2, M. Lyons2, N. Plevris1, P. Jenkinson1, C. Bisset1, J. Fulforth1, C. S. Chuah1, S. Minnis1, S-L. Gillespie1, W. Brindle1, C. Burgess3, P. Henderson3, D. Wilson3, C. Lees1

Created: Friday, 22 February 2019, 9:41 AM
DOP87: SUCNR1 a novel key protagonist in fistula development
Year: 2020
Source: ECCO'20 Vienna
Authors: Jesús Cosín-Roger
Created: Tuesday, 23 June 2020, 5:40 PM
DOP87: SUCNR1 a novel key protagonist in fistula development
Year: 2020
Source: ECCO'20 Vienna
Authors: Jesús Cosín-Roger
Created: Tuesday, 23 June 2020, 4:58 PM
Files: 1
DOP87: The Anti-TL1A Antibody PRA023 Demonstrated Proof-of-Concept in Crohn's Disease: Phase 2a APOLLO-CD Study Results
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Feagan , B.G.(1)*;Sands , B.(2);Siegel , C.A.(3);Dubinsky , M.(4);Longman , R.(5);Sabinho , J.(6);Laurent , O.(7);Luo , A.(7);Lu, JD.(7);Nguyen, D.(7);Towfic , F.(7);DuVall, A.(8);Woyranowski , M.(9);Al Kharrat , H.(10);McGovern, D.P.B.(11);
Created: Friday, 14 July 2023, 10:43 AM
DOP87: The Anti-TL1A Antibody PRA023 Demonstrated Proof-of-Concept in Crohn’s Disease: Phase 2a APOLLO-CD Study Results
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Brian Gordon Feagan
Created: Friday, 14 July 2023, 2:22 PM
DOP88 Visceral fat area correlates well with anti-TNFα drug levels and secondary loss of response in Crohn’s disease patients
Year: 2020
Source:

ECCO'20 Vienna

Authors:

Z. Lim1, C. Welman2, W. Raymond3, L. Thin1,3

Created: Thursday, 30 January 2020, 10:12 AM
DOP88: Effect of risankizumab on patient-reported outcomes in patients with Crohn’s Disease who had an inadequate response or intolerance to conventional and/or biologic treatments: Results from phase 3 MOTIVATE and ADVANCE trials
Year: 2021
Source: ECCO'21 Virtual
Authors: Peyrin-Biroulet, L.(1);Louis, E.(2);Ghosh, S.(3);Lee, S.D.(4);Griffith, J.(5);Wallace, K.(5);Berg, S.(5);Loftus Jr, E.V.(6)
Created: Wednesday, 2 June 2021, 4:12 PM
DOP88: Lipids drive myofibroblast activation and the epithelial-mesenchymal transition process in Crohn’s Disease.
Year: 2024
Source: ECCO'24 Stockholm
Authors: Rizzo, Giulia
Created: Tuesday, 30 April 2024, 5:03 PM
DOP88: Long-term real-world data of ustekinumab in Crohn’s Disease – the Stockholm ustekinumab study – STOCUSTE
Year: 2022
Source: ECCO'22
Authors: Bello, F.(1);Lördal, M.(2);Johansson, F.(3);Sabhan, H.(4);Muhsen, S.(2);Borin, A.(5);Forsberg, O.(6);Wennerström, C.(6);Söderman, C.(4);Almer, S.(1);
Created: Friday, 11 February 2022, 3:52 PM